Adverse Effects of Third-Dose Moderna Vaccination for Healthcare Workers of Udayana University Hospital, Bali, Indonesia

Authors

  • Putu Kintan Wulandari Udayana University
  • Richard Christian Suteja Udayana University
  • I Gede Purna Weisnawa Udayana University
  • Jerry Udayana University
  • I Komang Hotra Adiputra Udayana University
  • Giovanca Verentzia Purnama Udayana University
  • Darren Junior Udayana University
  • Dewa Ayu Fony Prema Shanti Udayana University
  • Cokorda Agung Wahyu Purnamasidhi Internal Medicine Department Udayana University / Udayana University Hospital, Indonesia

DOI:

https://doi.org/10.5195/ijms.2022.1773

Keywords:

Vaccine, Adverse effects, mRNA-1273, COVID-19, Healthcare workers, Booster Shot

Abstract

ABSTRACT.

Background

Since its first sighting in China at the end of 2019, COVID-19 had spread rapidly around the world, with no exception, to Indonesia. World Health Organization officially declared COVID-19 as a pandemic in March 2020. COVID-19 causes severe symptoms for those immunocompromised, making it an urgent matter to end the pandemic as soon as possible. In only 1 year since COVID-19 was found, the world has successfully developed COVID-19 vaccines which experts believe may bring an end to the pandemic. However, the vaccination also carries risk of adverse effect. 

Aim

The aim of this study is to report how the adverse effect of third dose mRNA-1273 vaccine in healthcare workers at Udayana University Hospital.

Methods

The descriptive study collects data from all healthcare workers in Udayana University Hospital receiving third-dose mRNA-1273 vaccine using online questionnaires. We excluded incomplete responds to maintain quality of data. This report comprises demographic characteristics, clinical history, and the adverse effects and was approved by the ethical committee of Udayana University.

Result

We received a respond rate of 86.9% (N=553) from a total of 636 healthcare workers who received the third-dose mRNA-1273 vaccine. Our respondents had a mean age of 37 (SD ± 7.81) years old. Most were female (55.8%) aging 20-29 years old (57.1%), and had an interval between their initial and third dose between 3-5 months (53.4%). Adverse effect most recorded was local pain (82.8%), followed by fever (56.4%), weakness/fatigue (39.3%), excessive sleepiness (32.5%), dizziness (30.1%), headache (27.6%), nausea/vomiting (21.5%), excessive hungerness (18,4%), other symptoms (11.0%)  and local erythema (10.4%). About 39.9% of the respondents felt the adverse effect 12-24 hours post-vaccination.   

Conclusion

Adverse effects following third-dose mRNA-1273 vaccination in healthcare workers of Udayana University Academic Hospital includes local pain, fever, weakness/fatigue, excessive sleepiness, dizziness, headache, nausea and vomiting, excessive hunger, and local erythema. Most of these symptoms occurred within the first 24 hours post-vaccination.

 

Key Words: Vaccine, Adverse Effect, mRNA-1273, COVID-19, Healthcare Worker

Metrics

Metrics Loading ...

Downloads

Published

2022-12-06 — Updated on 2023-01-02

How to Cite

Putu Kintan Wulandari, Richard Christian Suteja, I Gede Purna Weisnawa, Jerry, I Komang Hotra Adiputra, Giovanca Verentzia Purnama, Darren Junior, Dewa Ayu Fony Prema Shanti, & Cokorda Agung Wahyu Purnamasidhi. (2023). Adverse Effects of Third-Dose Moderna Vaccination for Healthcare Workers of Udayana University Hospital, Bali, Indonesia. International Journal of Medical Students, 10, S165. https://doi.org/10.5195/ijms.2022.1773

Issue

Vol 10 (2022): Supplement 1

Section

Abstracts of the WCMSR

Categories

License

Copyright (c) 2022 Putu Kintan Wulandari, Richard Christian Suteja, I Gede Purna Weisnawa, Jerry, I Komang Hotra Adiputra, Giovanca Verentzia Purnama, Darren Junior, Dewa Ayu Fony Prema Shanti, Cokorda Agung Wahyu Purnamasidhi

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

  1. The Author retains copyright in the Work, where the term “Work” shall include all digital objects that may result in subsequent electronic publication or distribution.
  2. Upon acceptance of the Work, the author shall grant to the Publisher the right of first publication of the Work.
  3. The Author shall grant to the Publisher and its agents the nonexclusive perpetual right and license to publish, archive, and make accessible the Work in whole or in part in all forms of media now or hereafter known under a Creative Commons Attribution 4.0 International License or its equivalent, which, for the avoidance of doubt, allows others to copy, distribute, and transmit the Work under the following conditions:
    1. Attribution—other users must attribute the Work in the manner specified by the author as indicated on the journal Web site; with the understanding that the above condition can be waived with permission from the Author and that where the Work or any of its elements is in the public domain under applicable law, that status is in no way affected by the license.
    2. The Author is able to enter into separate, additional contractual arrangements for the nonexclusive distribution of the journal's published version of the Work (e.g., post it to an institutional repository or publish it in a book), as long as there is provided in the document an acknowledgment of its initial publication in this journal.
    3. Authors are permitted and encouraged to post online a prepublication manuscript (but not the Publisher’s final formatted PDF version of the Work) in institutional repositories or on their Websites prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work. Any such posting made before acceptance and publication of the Work shall be updated upon publication to include a reference to the Publisher-assigned DOI (Digital Object Identifier) and a link to the online abstract for the final published Work in the Journal.
    4. Upon Publisher’s request, the Author agrees to furnish promptly to Publisher, at the Author’s own expense, written evidence of the permissions, licenses, and consents for use of third-party material included within the Work, except as determined by Publisher to be covered by the principles of Fair Use.
    5. The Author represents and warrants that:
      1. the Work is the Author’s original work;
      2. the Author has not transferred, and will not transfer, exclusive rights in the Work to any third party;
      3. the Work is not pending review or under consideration by another publisher;
      4. the Work has not previously been published;
      5. the Work contains no misrepresentation or infringement of the Work or property of other authors or third parties; and
      6. the Work contains no libel, invasion of privacy, or other unlawful matter.
    6. The Author agrees to indemnify and hold Publisher harmless from the Author’s breach of the representations and warranties contained in Paragraph 6 above, as well as any claim or proceeding relating to Publisher’s use and publication of any content contained in the Work, including third-party content.

Enforcement of copyright

The IJMS takes the protection of copyright very seriously.

If the IJMS discovers that you have used its copyright materials in contravention of the license above, the IJMS may bring legal proceedings against you seeking reparation and an injunction to stop you using those materials. You could also be ordered to pay legal costs.

If you become aware of any use of the IJMS' copyright materials that contravenes or may contravene the license above, please report this by email to contact@ijms.org

 

Infringing material

If you become aware of any material on the website that you believe infringes your or any other person's copyright, please report this by email to contact@ijms.org

Most read articles by the same author(s)